January 6, 2026 – 5.45 pm – Diagnostic Medical Systems (Euronext Growth Paris: FR0012202497 – ALDMS), a specialist in high-performance medical imaging systems for digital radiology and bone densitometry, communicates the half-year results of the liquidity contract entrusted by DIAGNOSTIC MEDICAL SYSTEMS to NATIXIS ODDO BHF dated May 7, 2025.

As of 31/12/2025, the following resources were included in the dedicated liquidity account:

• 110 630 Shares
• 102 349 Euros

It should be noted that when the contract was set up, the following resources were included in the dedicated liquidity account:

• 150 000 Shares
• 50 000 Euros

Over the period from 01/07/2025 to 31/12/2025 were executed:

• 1 155 Purchase transactions 
• 1 153 Sale Transactions

Over the same period, the volumes traded represented:

• 248 152 Shares and 330 540 euros on purchase
• 253 627 Shares and 342 117 euros for sale

UPCOMING EVENTS^* :

• 19/01/2026 2025 Annual revenue 2025
• 14/04/2026 2025 Annual results
• 21/04/2026 Q1 2026 revenue

The publications will take place after the close of the Euronext Paris market.
*Provisional schedule subject to change. Visit the DMS Group website.

Find financial information on our investor area: www.dms.com

Receive free financial information from DMS Group by registering on www.actusnews.com

ABOUT DMS GROUP

DMS Group is a French digital radiology manufacturer, internationally oriented, recognized as a key player and a key partner in the value chain, both for the quality of its solutions, and for its flexibility, ingenuity and responsible values.

In 2024, DMS Group achieved a consolidated turnover of €46.1 million, more than 75% of which was international, with a presence on all continents through a network of more than 140 national distributors.

DMS Group is listed on the Euronext Growth Paris market (ISIN: FR0012202497 - ticker: ALDMS) and is eligible for the PEA PME-ETI.

DMS Group is part of the ETIncelles program for SMEs that have the ambition and the desire to become mid-caps.